Table 1.
Effects of BCL2 overexpression, or Bcl2l11 or Fas mutation on T-cell development
| T-cell subset | Kdelr1 | — | EμBCL2-25+ | Bcl2l11−/− | Faslpr/lpr |
| CD3ε+ (×10e6) | +/dgy | 9.1 ± 0.91 | 15.5 ± 1.6 | 17.5 ± 1.7 | 12.2 ± 3.1 |
| dgy/dgy | 3.0 ± 0.27 | 6.8 ± 0.76 | 11.1 ± 1.7 | 10.0 ± 1.3 | |
| P | 0.005 | 0.006 | 0.04 | 0.54 | |
| CD4+ (×10e6) | +/dgy | 4.5 ± 1.3 | 7.6 ± 0.9 | 8.0 ± 1.3 | 5.9 ± 1.3 |
| dgy/dgy | 1.3 ± 0.33 | 2.7 ± 0.35 | 4.8 ± 0.88 | 6.7 ± 1.1 | |
| P | 0.08 | 0.007 | 0.11 | 0.63 | |
| CD8+ (×10e6) | +/dgy | 4.3 ± 0.87 | 6.8 ± 0.59 | 6.0 ± 0.21 | 1.4 ± 0.47 |
| dgy/dgy | 1.5 ± 0.41 | 2.5 ± 0.19 | 2.9 ± 0.35 | 1.9 ± 0.19 | |
| P | 0.04 | 0.003 | 0.0007 | 0.35 | |
| CD4+CD44MFI | +/dgy | 214 ± 54 | 156 ± 5 | 121 ± 14 | 327 ± 33 |
| dgy/dgy | 264 ± 25 | 237 ± 6 | 199 ± 23 | 388 ± 15 | |
| P | 0.44 | 0.00008 | 0.04 | 0.17 | |
| CD4+CD3εMFI | +/dgy | 2,773 ± 250 | 3,189 ± 15 | 2,916 ± 55 | 1,760 ± 73 |
| dgy/dgy | 2,219 ± 85 | 2,181 ± 63 | 2,250 ± 177 | 2,025 ± 50 | |
| P | 0.11 | 0.0003 | 0.03 | 0.03 | |
| CD8+CD44MFI | +/dgy | 91 ± 6 | 98 ± 3 | 92 ± 8 | 247 ± 13 |
| dgy/dgy | 327 ± 73 | 391 ± 39 | 299 ± 40 | 395 ± 36 | |
| P | 0.048 | 0.005 | 0.01 | 0.02 | |
| CD8+CD3εMFI | +/dgy | 1,414 ± 141 | 1,712 ± 25 | 1,614 ± 9 | 910 ± 21 |
| dgy/dgy | 999 ± 39 | 977 ± 31 | 1,052 ± 93 | 873 ± 32 | |
| P | 0.06 | 0.000003 | 0.009 | 0.38 |
Splenic T cells from mice with a T-cell–expressed EμBCL2-25 transgene, Bcl2l11 deletion, or Faslpr/lpr mutation were analyzed by flow cytometry. MFI, median fluorescence intensity. Data are from one experiment, with four mice per genotype (SEM). P values below the Bonferroni correction threshold (0.0018) are in bold.